Rebecca Previs’ Post

View profile for Rebecca Previs, graphic

Gynecologic Oncologist; Surgeon-Scientist, Director of Medical Affairs

In case you missed the work published by Mary K Nesline et al. last week published in Oncology and Therapy... The Labcorp Oncology medical affairs team examined the downstream effect of single-gene testing for guideline-recommended biomarkers on comprehensive genomic profiling in non–small cell lung cancer (NSCLC). “Our findings have significant implications for patients with NSCLC...Undertesting and incomplete testing for oncogenic driver mutations can lead not only to underutilization of frontline targeted therapy, but also to improper use of upfront immune checkpoint inhibitors in patients with actionable genomic variants who can derive clinically meaningful benefits from biomarker-driven targeted therapy.” Bottomline: CGP should be performed on every advanced and metastatic NSCLC tumor. Want to read more? https://lnkd.in/eQebDqeS Vivek Subbiah, MD Kyle Strickland Heidi Ko, DO Paul DePietro Maureen Cooper Nini Wu, MD Jeffrey Conroy Sarabjot Pabla Zachary Wallen, PhD Pratheesh Sathyan PhD Kamal S. Saini Marcia Eisenberg Brian Caveney Eric Severson Shakti Ramkissoon

Experts Sound the Alarm on Lack of Comprehensive Genomic Profiling in NSCLC

Experts Sound the Alarm on Lack of Comprehensive Genomic Profiling in NSCLC

ajmc.com

Pratheesh Sathyan PhD

Head of Illumina AMR Oncology Medical Affairs

7mo

Thank you Labcorp team for this amazing collaboration!!!

Nikki Martin

Patient Advocacy Leader | Promoting Timely, Accurate, and Reimbursed Biomarker Testing in Lung Cancer Care

6mo

This is such a creative and unique paper that speaks volumes about LabCorp's commitment to improving patient access to guideline-recommended preferred levels of testing with broad multi-gene panels. I would be interested in knowing what qualitative insights there are from discussing this with providers who switched from single gene to multi-gene. What were their barriers to this in the first place? @Becca - any chance you will share those insights?

Like
Reply
Jeffrey Rosenfeld, PhD, MBA 🚲

Genomics Strategy | Biotech Due Diligence | Biomarkers and Bioinformatics | Principal Consultant

7mo

Rebecca Previs. I totally agree with this. Genomic sequencing should be done on all tumors. One important factor to be analyzed is the age of the physician. I assume younger physicians are more open to changes in testing and treatment

Pierre del Moral, PhD MBA

Marketing Leader | Business Strategy | Oncology | Genetic Disease | NIPT | Clinical | Genomics | Diagnostics

7mo

Such an important call for CGP testing and publication

Julie Wiedower, PhDc, CGC

Genetic Counselor, Genomic Policy and Value Researcher, Utilization Management, Medical Affairs, Managed Care and Market Access for Genetic Testing

6mo

Absolutely! This has been shown in SEER data, RWE clinical databases and clinical studies!!!! I only hope that coverage policies will move to expand coverage of CGP and remove barriers to testing!

Like
Reply
Jason Gottwals

Genomics | Diagnostics | Oncology | Therapeutics

7mo

100%!!!

Like
Reply
Alex Armasu

Founder & CEO, Group 8 Security Solutions Inc. DBA Machine Learning Intelligence

7mo

Thanks for sharing!

See more comments

To view or add a comment, sign in

Explore topics